Biomarkers of bone fragility in type 2 diabetes may be on the horizon
The number of people with diabetes has nearly quadrupled in the last four decades and is now close to 425 million. Type 2 diabetes accounts for about 90 % of all cases and growing evidence suggests that it is an independent risk factor for bone fragility and fragility fractures despite a higher bone mineral density. Given the divergence from classical risk factors for osteoporosis, it is critical to understand the mechanisms to develop better methods for prevention, diagnosis, and treatment. FIDELIO is tackling the challenge with the help of young researchers. The partnership will enhance understanding of bone fragility in type 2 diabetes for the development of biomarkers for detection and treatment planning.
Fields of science
Funding SchemeMSCA-ITN-ETN - European Training Networks
5230 Odense M
S10 2TN Sheffield
3015 GD Rotterdam
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.